Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...
PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb ...
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a leading pharmaceutical company in Greater China, announced that they have entered into an exclusive global license ...
Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...
Sanofi will lead the phase III clinical development program. Merck Enters Obesity Space With Hansoh Pharma Deal Merck announced that it is in-licensing exclusive global rights to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback